Emcure Pharmaceuticals Cuts Poviztra Price by 55% for Wider Access
Filing Summary
Emcure Pharmaceuticals Ltd. has announced a significant price reduction for its weight management drug, Poviztra® (semaglutide injection), effective April 3, 2026. The starting dose price has been reduced by 55%, with the new monthly cost set at Rs. 3,999. This adjustment aims to make the drug more accessible across India. The price revision applies to all dosage strengths, with an average reduction of 47%. Emcure is the first Indian company to distribute this drug, which is used for obesity management, in collaboration with Novo Nordisk.
Emcure Pharmaceuticals Ltd. has announced a price reduction for its weight management drug, Poviztra® (semaglutide injection), effective from April 3, 2026. The starting dose price has been reduced by 55%, with the new monthly cost set at Rs. 3,999 for four weekly doses. This price adjustment is part of Emcure’s strategy to expand patient access to the drug across India.
The price revision affects all dosage strengths of Poviztra®, with an average reduction of 47% across the board. The revised monthly prices for the different dosages are as follows: 0.25 mg at Rs. 3,999, 0.5 mg at Rs. 4,999, 1 mg at Rs. 5,999, 1.7 mg at Rs. 7,999, and 2.4 mg at Rs. 8,999. These prices are inclusive of taxes. The drug is available in a once-weekly pen device, providing convenience and precise dosing.
Emcure Pharmaceuticals is the first Indian company to exclusively distribute and commercialize Poviztra®, a second brand of Novo Nordisk’s semaglutide injection for obesity. The drug is backed by extensive clinical and real-world evidence, having been on the market for nearly a decade. It has been studied in nearly 50 clinical trials and used globally, with over 49 million patient years of exposure.
The price reduction is timely, as obesity and weight-related health conditions are significant public health challenges in India. The innovator biologic rDNA semaglutide molecule is used to manage obesity, which is linked to over 230 health complications. These include cardiovascular disease, type 2 diabetes, hypertension, and more. Emcure’s decision to lower the price aims to improve access to this established treatment and address the growing obesity epidemic in India.
The revised pricing will be implemented starting April 3, 2026. Emcure Pharmaceuticals has taken this step to make scientifically validated weight-management therapies more accessible and affordable to a broader patient base. The company emphasizes the importance of improving access to semaglutide to tackle the obesity epidemic in India.
About Emcure Pharmaceuticals Limited: Emcure Pharmaceuticals Ltd. is a leading Indian pharmaceutical company headquartered in Pune. It develops, manufactures, and markets a broad range of pharmaceutical products globally. Known for its commitment to innovation and quality, Emcure focuses on improving patient health and well-being across several therapeutic areas. Established in 1981, it ranks as the 13th largest pharma company in India by domestic sales as of October 2025. Emcure operates in over 70 countries, including Europe and Canada.